The great escape: tumour cell plasticity in resistance to targeted therapy
S Boumahdi, FJ de Sauvage - Nature reviews Drug discovery, 2020 - nature.com
The success of targeted therapies in cancer treatment has been impeded by various
mechanisms of resistance. Besides the acquisition of resistance-conferring genetic …
mechanisms of resistance. Besides the acquisition of resistance-conferring genetic …
Small cell lung cancer transformation: From pathogenesis to treatment
X Yin, Y Li, H Wang, T Jia, E Wang, Y Luo, Y Wei… - seminars in Cancer …, 2022 - Elsevier
Small cell lung cancer (SCLC) is a type of neuroendocrine tumor with high malignancy and
poor prognosis. Besides the de novo SCLC, there is transformed SCLC, which has similar …
poor prognosis. Besides the de novo SCLC, there is transformed SCLC, which has similar …
Small cell lung cancer: Subtypes and therapeutic implications
WZ Wang, A Shulman, JM Amann, DP Carbone… - Seminars in cancer …, 2022 - Elsevier
Small cell lung cancer (SCLC) is an extremely aggressive neuroendocrine tumor,
accounting for approximated 13% of all lung cancer cases. SCLC is characterized by rapid …
accounting for approximated 13% of all lung cancer cases. SCLC is characterized by rapid …
Future options of molecular-targeted therapy in small cell lung cancer
AB Schulze, G Evers, A Kerkhoff, M Mohr… - Cancers, 2019 - mdpi.com
Lung cancer is the leading cause of cancer-related deaths worldwide. With a focus on
histology, there are two major subtypes: Non-small cell lung cancer (NSCLC)(the more …
histology, there are two major subtypes: Non-small cell lung cancer (NSCLC)(the more …
[HTML][HTML] Transformation of ALK-positive NSCLC to SCLC after alectinib resistance and response to combined atezolizumab: a case report
G Xia, J Huang, J Ni, M Song, J Zhang… - Translational Lung …, 2023 - ncbi.nlm.nih.gov
Background The genotypic and histological evolution of non-small cell lung cancer (NSCLC)
to small cell lung cancer (SCLC) has been described as a mechanism of acquired …
to small cell lung cancer (SCLC) has been described as a mechanism of acquired …
From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC)
L Fabbri, A Di Federico, M Astore, V Marchiori… - Diagnostics, 2023 - mdpi.com
Following the results of the CROWN phase III trial, the third-generation macrocyclic ALK
inhibitor lorlatinib has been introduced as a salvage option after the failure of a first-line TKI …
inhibitor lorlatinib has been introduced as a salvage option after the failure of a first-line TKI …
[HTML][HTML] Challenges in the use of targeted therapies in non-small cell lung cancer
J Rivera-Concepcion, D Uprety… - Cancer Res Treat, 2022 - synapse.koreamed.org
Precision oncology has fundamentally changed how we diagnose and treat cancer. In
recent years, there has been a significant change in the management of patients with …
recent years, there has been a significant change in the management of patients with …
Acquired resistance in lung cancer
A Tulpule, TG Bivona - Annual Review of Cancer Biology, 2020 - annualreviews.org
The last decade has witnessed a transformation in the treatment of advanced-stage lung
cancer from a largely palliative approach to one where long-term durable remissions and …
cancer from a largely palliative approach to one where long-term durable remissions and …
Transformation from adenocarcinoma to squamous cell lung carcinoma with MET amplification after lorlatinib resistance: A case report
S Ueda, T Shukuya, T Hayashi, M Suzuki… - Thoracic …, 2021 - Wiley Online Library
To date, several studies have described the mechanism of resistance to first‐or second‐
generation anaplastic lymphoma kinase (ALK) inhibitors. Secondary ALK mutations, ALK …
generation anaplastic lymphoma kinase (ALK) inhibitors. Secondary ALK mutations, ALK …
ALK-rearranged lung adenocarcinoma transformation into high-grade large cell neuroendocrine carcinoma: Clinical and molecular description of two cases
Discussion Although most patients with ALK-rearranged LUAD benefit from ALK-TKIs,
acquired resistance occurs eventually. Approximately 50–66% of acquired resistance …
acquired resistance occurs eventually. Approximately 50–66% of acquired resistance …